BAUSCH + LOMB CORP (BLCO)
CA0717051076 - Common Stock
Taking everything into account, BLCO scores 3 out of 10 in our fundamental rating. BLCO was compared to 187 industry peers in the Health Care Equipment & Supplies industry. BLCO has a medium profitability rating, but doesn't score so well on its financial health evaluation. BLCO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BLCO had positive earnings in the past year.
In the past year BLCO had a positive cash flow from operations.
In multiple years BLCO reported negative net income over the last 5 years.
BLCO had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
BLCO has a better Return On Assets (-3.44%) than 65.24% of its industry peers.
With a decent Return On Equity value of -7.01%, BLCO is doing good in the industry, outperforming 65.24% of the companies in the same industry.
The Return On Invested Capital of BLCO (1.34%) is better than 69.52% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BLCO is significantly below the industry average of 8.30%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.44% | ||
| ROE | -7.01% | ||
| ROIC | 1.34% |
ROA(3y)-0.07%
ROA(5y)0.45%
ROE(3y)-0.59%
ROE(5y)0.21%
ROIC(3y)2.06%
ROIC(5y)2.3%
1.3 Margins
The Operating Margin of BLCO (4.38%) is better than 70.59% of its industry peers.
BLCO's Operating Margin has declined in the last couple of years.
BLCO has a better Gross Margin (60.85%) than 60.43% of its industry peers.
BLCO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.38% | ||
| PM (TTM) | N/A | ||
| GM | 60.85% |
OM growth 3Y-13.3%
OM growth 5Y-16.21%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-1.21%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BLCO is destroying value.
BLCO has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, BLCO has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.05, we must say that BLCO is in the distress zone and has some risk of bankruptcy.
BLCO has a Altman-Z score (1.05) which is in line with its industry peers.
A Debt/Equity ratio of 0.71 indicates that BLCO is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.71, BLCO is not doing good in the industry: 73.80% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.05 |
ROIC/WACC0.16
WACC8.21%
2.3 Liquidity
BLCO has a Current Ratio of 1.65. This is a normal value and indicates that BLCO is financially healthy and should not expect problems in meeting its short term obligations.
BLCO has a worse Current ratio (1.65) than 79.68% of its industry peers.
BLCO has a Quick Ratio of 1.01. This is a normal value and indicates that BLCO is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of BLCO (1.01) is worse than 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
The earnings per share for BLCO have decreased strongly by -19.51% in the last year.
BLCO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.14%.
BLCO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.50% yearly.
EPS 1Y (TTM)-19.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.78%
Revenue 1Y (TTM)15.14%
Revenue growth 3Y6.71%
Revenue growth 5Y2.5%
Sales Q2Q%17.49%
3.2 Future
The Earnings Per Share is expected to grow by 25.51% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 7.48% on average over the next years.
EPS Next Y-16.51%
EPS Next 2Y8.65%
EPS Next 3Y13.76%
EPS Next 5Y25.51%
Revenue Next Year16.44%
Revenue Next 2Y11.29%
Revenue Next 3Y9.07%
Revenue Next 5Y7.48%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 30.30 indicates a quite expensive valuation of BLCO.
Compared to the rest of the industry, the Price/Earnings ratio of BLCO indicates a somewhat cheap valuation: BLCO is cheaper than 79.14% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of BLCO to the average of the S&P500 Index (30.79), we can say BLCO is valued inline with the index average.
The Price/Forward Earnings ratio is 22.89, which indicates a rather expensive current valuation of BLCO.
BLCO's Price/Forward Earnings ratio is rather cheap when compared to the industry. BLCO is cheaper than 81.82% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BLCO to the average of the S&P500 Index (22.21), we can say BLCO is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.3 | ||
| Fwd PE | 22.89 |
4.2 Price Multiples
BLCO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BLCO is cheaper than 82.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 18.52 |
4.3 Compensation for Growth
BLCO's earnings are expected to grow with 13.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.65%
EPS Next 3Y13.76%
5. Dividend
5.1 Amount
No dividends for BLCO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BAUSCH + LOMB CORP
NYSE:BLCO (9/19/2024, 7:00:00 PM)
After market: 20 0 (0%)20
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.04B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.3 | ||
| Fwd PE | 22.89 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.44% | ||
| ROE | -7.01% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 4.38% | ||
| PM (TTM) | N/A | ||
| GM | 60.85% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-19.51%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-16.51%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)15.14%
Revenue growth 3Y6.71%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y